IGOR SHAPOVAL: Open Payments
NPI 1962282749 · CLACKAMAS, OR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,231 in 51 payments from 12 companies in 2025. Trend: 2023 $0 · 2024 $239 · 2025 $1,231
Food & beverage: $1,231
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 10 | $317 |
| Amgen Inc. | 16 | $233 |
| Aimmune Therapeutics, Inc. | 9 | $225 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $196 |
| Novartis Pharmaceuticals Corporation | 2 | $64 |
| Axsome Therapeutics, Inc. | 2 | $45 |
| ABBVIE INC. | 2 | $41 |
| PFIZER INC. | 1 | $29 |
| Edwards Lifesciences Corporation | 1 | $27 |
| Sumitomo Pharma America, Inc. | 1 | $21 |
Products named: ZENPEP, XIFAXAN, BREZTRI, EVENITY, AIRSUPRA, LEQVIO, OTEZLA, Auvelity.
Industry payments across OR — which companies pay providers there.
